diflorasone

Therapeutic Classification: corticosteroids

Pharmacologic Classification: corticosteroids

REMS

Management of inflammation and pruritis associated with various allergic/immunologic skin problems.

Suppresses normal immune response and inflammation.

Therapeutic effects:

Suppression of dermatologic inflammation and immune processes.

Absorption: Minimal. Prolonged use on large surface areas, application of large amounts, or use of occlusive dressings may increase systemic absorption.

Distribution: Remains primarily at site of action.

Metabolism/Excretion: Usually metabolized in skin.

Half-Life: Unknown.

(response depends on condition being treated)

ROUTE	ONSET	PEAK	DURATION
Topical	min–hrs	hrs–days	hrs–days

Contraindicated in:

Hypersensitivity or known intolerance to corticosteroids or components of vehicles (ointment or cream base, preservative, alcohol);
Untreated bacterial or viral infections.

Use Cautiously in:

Hepatic dysfunction;
Diabetes mellitus, cataracts, glaucoma, or tuberculosis (use of large amounts of high-potency agents may worsen condition);
Patients with pre-existing skin atrophy;
OB: Chronic high-dose usage may result in adrenal suppression in mother, growth suppression in children; children may be more susceptible to adrenal and growth suppression.

Derm: atrophy, allergic contact dermatitis, burning, dryness, edema, folliculitis, hypersensitivity reactions, hypertrichosis, hypopigmentation, irritation, maceration, miliaria, perioral dermatitis, secondary infection, striae

Misc: adrenal suppression (use of occlusive dressings, long-term therapy)

Drug-drug:

None significant.

(Adults ): Apply to affected area(s) 1–4 times daily (depends on condition being treated).
(Children ): Apply to affected area(s) once daily.

(Generic available)

Cream: 0.05%
Ointment: 0.05%

Assess affected skin before and daily during therapy. Note degree of inflammation and pruritus. Notify health care professional if symptoms of infection (increased pain, erythema, purulent exudate) develop.

Lab Test Considerations:

Periodic adrenal function tests may be ordered to assess degree of hypothalamic-pituitary-adrenal (HPA) axis suppression in chronic topical therapy if suspected. Children and patients with dose applied to a large area, using an occlusive dressing, or using high-potency products are at highest risk for HPA suppression.
- May cause increased serum and urine glucose concentrations if significant absorption occurs.

Choice of vehicle depends on site and type of lesion. Ointments are more occlusive and preferred for dry, scaly lesions. Creams should be used on oozing or intertriginous areas, where the occlusive action of ointments might cause folliculitis or maceration. Creams may be preferred for aesthetic reasons even though they may be more drying to skin than ointments.
Apply ointment orcream sparingly as a thin film to clean, slightly moist skin. Wear gloves. Apply occlusive dressing only if specified by physician or other health care professional.

Instruct patient on correct technique of medication administration. Emphasize importance of avoiding the eyes. If a dose is missed, it should be applied as soon as remembered unless almost time for the next dose.
Caution patient to use only as directed. Avoid using cosmetics, bandages, dressings, or other skin products over the treated area unless directed by health care professional.
Advise parents of pediatric patients not to apply tight-fitting diapers or plastic pants on a child treated in the diaper area; these garments work like an occlusive dressing and may cause more of the drug to be absorbed.
Advise patient to consult health care professional before using medicine for condition other than indicated.
Instruct patient to inform health care professional if symptoms of underlying disease return or worsen or if symptoms of infection develop.
Caution women that medication should not be used extensively, in large amounts, or for protracted periods if they are pregnant or planning to become pregnant.

Resolution of skin inflammation, pruritus, or other dermatologic conditions.

NDC Code

0168- E. FOUGERA and CO., A division of Fougera Pharmaceuticals Inc.
- 0168-0242- Diflorasone Diacetate
  - 0168-0242-15- 15 g in 1 TUBE (0168-0242-15)

0168- E. FOUGERA and CO., A division of Fougera Pharmaceuticals Inc.
- 0168-0242- Diflorasone Diacetate
  - 0168-0242-30- 30 g in 1 TUBE (0168-0242-30)

0168- E. FOUGERA and CO., A division of Fougera Pharmaceuticals Inc.
- 0168-0242- Diflorasone Diacetate
  - 0168-0242-60- 60 g in 1 TUBE (0168-0242-60)

0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
- 0168-0243- Diflorasone Diacetate
  - 0168-0243-15- 1 TUBE in 1 CARTON (0168-0243-15) > 15 g in 1 TUBE

0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
- 0168-0243- Diflorasone Diacetate
  - 0168-0243-30- 1 TUBE in 1 CARTON (0168-0243-30) > 30 g in 1 TUBE

0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
- 0168-0243- Diflorasone Diacetate
  - 0168-0243-60- 1 TUBE in 1 CARTON (0168-0243-60) > 60 g in 1 TUBE

0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
- 0168-0353- Diflorasone Diacetate
  - 0168-0353-30- 1 TUBE in 1 CARTON (0168-0353-30) > 30 g in 1 TUBE

0168- E. Fougera and Co. a division of Fougera Pharmaceuticals Inc.
- 0168-0353- Diflorasone Diacetate
  - 0168-0353-60- 1 TUBE in 1 CARTON (0168-0353-60) > 60 g in 1 TUBE

10337- PharmaDerm a division of Fougera Pharmaceuticals Inc.
- 10337-395- ApexiCon E
  - 10337-395-08- 2 g in 1 TUBE (10337-395-08)

10337- PharmaDerm a division of Fougera Pharmaceuticals Inc.
- 10337-395- ApexiCon E
  - 10337-395-30- 1 TUBE in 1 CARTON (10337-395-30) > 30 g in 1 TUBE

10337- PharmaDerm a division of Fougera Pharmaceuticals Inc.
- 10337-395- ApexiCon E
  - 10337-395-60- 1 TUBE in 1 CARTON (10337-395-60) > 60 g in 1 TUBE

10337- PharmaDerm a division of Fougera Pharmaceuticals Inc.
- 10337-395- ApexiCon E
  - 10337-395-66- 6 TUBE in 1 CARTON (10337-395-66) > 2 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1295- Diflorasone Diacetate
  - 51672-1295-1- 1 TUBE in 1 CARTON (51672-1295-1) > 15 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1295- Diflorasone Diacetate
  - 51672-1295-2- 1 TUBE in 1 CARTON (51672-1295-2) > 30 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1295- Diflorasone Diacetate
  - 51672-1295-3- 1 TUBE in 1 CARTON (51672-1295-3) > 60 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1296- Diflorasone Diacetate
  - 51672-1296-1- 1 TUBE in 1 CARTON (51672-1296-1) > 15 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1296- Diflorasone Diacetate
  - 51672-1296-2- 1 TUBE in 1 CARTON (51672-1296-2) > 30 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-1296- Diflorasone Diacetate
  - 51672-1296-3- 1 TUBE in 1 CARTON (51672-1296-3) > 60 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-5292- psorcon
  - 51672-5292-3- 1 TUBE in 1 CARTON (51672-5292-3) > 60 g in 1 TUBE

51672- Taro Pharmaceuticals U.S.A., Inc.
- 51672-5292- psorcon
  - 51672-5292-5- 1 TUBE in 1 CARTON (51672-5292-5) > 5 g in 1 TUBE

52565- Teligent Pharma, Inc.
- 52565-063- Diflorasone Diacetate
  - 52565-063-15- 1 TUBE in 1 CARTON (52565-063-15) > 15 g in 1 TUBE

52565- Teligent Pharma, Inc.
- 52565-063- Diflorasone Diacetate
  - 52565-063-30- 1 TUBE in 1 CARTON (52565-063-30) > 30 g in 1 TUBE

52565- Teligent Pharma, Inc.
- 52565-063- Diflorasone Diacetate
  - 52565-063-60- 1 TUBE in 1 CARTON (52565-063-60) > 60 g in 1 TUBE

61748- VersaPharm Incorporated
- 61748-350- Diflorasone Diacetate
  - 61748-350-15- 1 TUBE in 1 CARTON (61748-350-15) > 15 g in 1 TUBE

61748- VersaPharm Incorporated
- 61748-350- Diflorasone Diacetate
  - 61748-350-30- 1 TUBE in 1 CARTON (61748-350-30) > 30 g in 1 TUBE

61748- VersaPharm Incorporated
- 61748-350- Diflorasone Diacetate
  - 61748-350-60- 1 TUBE in 1 CARTON (61748-350-60) > 60 g in 1 TUBE

71800- Innovida Pharmaceutique Corporation
- 71800-009- Diflorasone Diacetate
  - 71800-009-60- 1 TUBE in 1 CARTON (71800-009-60) > 60 g in 1 TUBE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Code ⬆